KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Impact of Dapagliflozin on Cardiometabolic Outcomes After Acute Myocardial Infarction According to Baseline Glycemic Status and Body Mass Index: Subanalyses of the DAPA-MI Trial.

J Am Heart Assoc · 2025-Aug-05 · PMID 40728174

Panel C质量警告待 EXE 对齐验证

NYHA class III-IV symptoms

Figure 6. Cumulative probability of New York Heart Association class III to IV symptoms occurring during follow‐up in dapagliflozin and placebo groups according to baseline HbA1c or body mass index. NYHA class III‐IV symptoms in (A) the whole subanalysis cohort and (B‐F) subgroups of this cohort with the following baseline characteristics: (B) HbA1c < 5.7%, (C) HbA1c 5.7 to < 6.5%, (D) BMI < 25, (E) BMI 25 to < 30, and (F) BMI ≥30. BMI indicates body mass index; 1‐yr KM% indicates Kaplan–Meier cumulative incidence at 1 year; Dapa, dapagliflozin; HbA1c, hemoglobin A1c; and NYHA, New York Heart Association.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.33
质量通过否
预期曲线2
实际曲线1
X 范围0 – 24
Y 范围0 – 10

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

匹配 18 行
Curve序号X (norm)Y (norm)X (real)Y (real)X (pixel)Y (pixel)
210.64060.946815.37509.4681149164
220.64580.946815.50009.4681150164
230.65100.946815.62509.4681151164
240.65620.946815.75009.4681152164
250.66150.946815.87509.4681153164
260.66670.946816.00009.4681154164
270.67190.946816.12509.4681155164
280.67710.468116.25004.6809156209
290.68230.468116.37504.6809157209
2100.68750.468116.50004.6809158209
2110.69270.468116.62504.6809159209
2120.69790.468116.75004.6809160209
2130.70310.468116.87504.6809161209
2140.70830.468117.00004.6809162209
2150.71350.468117.12504.6809163209
2160.71880.468117.25004.6809164209
2170.72400.468117.37504.6809165209
2180.72920.468117.50004.6809166209
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0quality_warning待验证12026-07-23T17:30:40+00:00